换一批Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
第一作者：
A Ari,Hakimi
第一单位：
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
作者：
医学主题词
老年人(Aged);癌, 肾细胞(Carcinoma, Renal Cell);细胞转化, 肿瘤(Cell Transformation, Neoplastic);染色体, 人, 3对(Chromosomes, Human, Pair 3);临床试验(主题)(Clinical Trials as Topic);DNA结合蛋白质类(DNA-Binding Proteins);无病生存(Disease-Free Survival);后成说, 遗传(Epigenesis, Genetic);女(雌)性(Female);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);组蛋白赖氨酸N-甲基转移酶(Histone-Lysine N-Methyltransferase);人类(Humans);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);肿瘤分期(Neoplasm Staging);核蛋白质类(Nuclear Proteins);转录因子(Transcription Factors);肿瘤抑制蛋白质类(Tumor Suppressor Proteins);泛素硫酯酶(Ubiquitin Thiolesterase)
DOI
10.1158/1078-0432.CCR-12-3886
PMID
23620406
发布时间
2022-03-31
- 浏览20
Clinical cancer research
3259-67页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
